CytomX Therapeutics (CTMX) Cash & Equivalents (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Cash & Equivalents came in at $28.8 million in Q1 2026, down 39.44% YoY from $47.6 million in Q1 2025, and up 127.58% on a QoQ basis from $12.7 million in Q4 2025.
CytomX Therapeutics (CTMX) Cash & Equivalents (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Cash & Equivalents data on file, last reported at $28.8 million in Q1 2026.
- Quarterly Cash & Equivalents fell 39.44% year-over-year to $28.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.8 million (down 39.44% YoY) and the FY2025 annual result came in at $12.7 million, down 66.71% from the prior year.
- Cash & Equivalents rose to $28.8 million in Q1 2026, from $12.7 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $193.6 million in Q4 2022 to a low of $12.7 million in Q4 2025.
- A 5-year average of $62.9 million and a median of $43.2 million in 2024 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 91.13% — and 2024, when it soared 121.61%.
- Tracing CTMX's Cash & Equivalents over 5 years: stood at $193.6 million in 2022, then sank by 91.13% to $17.2 million in 2023, then soared by 121.61% to $38.1 million in 2024, then slumped by 66.71% to $12.7 million in 2025, then surged by 127.58% to $28.8 million in 2026.
- The last three Cash & Equivalents figures came in at $28.8 million (Q1 2026), $12.7 million (Q4 2025), and $34.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 17.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.22 Mn |
| Mar 31, 2026 | 28.83 Mn |
| Dec 31, 2025 | 12.67 Mn |
| Sep 30, 2025 | 34.19 Mn |
| Jun 30, 2025 | 49.04 Mn |
| Mar 31, 2025 | 47.60 Mn |
| Dec 31, 2024 | 38.05 Mn |
| Sep 30, 2024 | 40.58 Mn |
| Jun 30, 2024 | 43.25 Mn |
| Mar 31, 2024 | 36.19 Mn |
| Dec 31, 2023 | 17.17 Mn |
| Sep 30, 2023 | 26.02 Mn |
| Jun 30, 2023 | 57.54 Mn |
| Mar 31, 2023 | 56.36 Mn |
| Dec 31, 2022 | 193.65 Mn |
| Sep 30, 2022 | 95.04 Mn |
| Jun 30, 2022 | 129.29 Mn |
| Mar 31, 2022 | 163.49 Mn |
| Dec 31, 2021 | 205.53 Mn |
| Sep 30, 2021 | 236.28 Mn |